All In Biotech

Drug Trial Radar · NCT06275763

Optimal Medical Treatment of Difficult-to-treat Hypertension

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,500

Planned (sponsor's estimate)

Start

Oct 20, 2023

Primary completion

Dec 1, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
National Institute of Cardiology, Warsaw, PolandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate best medical management to achieve the BP goals of ESC/ESH (120-129 / 70-79 mmHg) in HT patients who are \<65 years old and ineffectively treated (BP ≥ 130/80 mg) with 3 or more antihypertensive drugs

Conditions

  • Hypertension

Interventions

  • Phase C: EplerenoneDrug

    Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide

  • Phase C: SpironolactoneDrug

    Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide

  • Phase C: TorasemideDrug

    Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone

  • Phase B: Triplixam / Elestar HCTDrug

    Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).

  • Phase A: Confirmation of uncontrolled hypertensionDiagnostic test

    Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients with uncontrolled BP on ABPMTime frame: First week of the patients' participation in the study
  2. Patients with controlled BP after 12 weeks on triple SPCTime frame: Next 12 weeks of the patients' participation in the study
  3. Systolic BP reduction on 4th antihypertensive drugTime frame: Last 24 weeks of the patients' participation in the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Cardiology

    Warsaw, Masovian Voivodeship, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.